Summary: Exiqon A/S (OMX: EXQ) calls for an ordinary general meeting on 14
April 2010 at 3 pm (CET) at the company's address, Skelstedet 16, DK-2950
Vedbaek, Denmark. A copy of the notice and the proposals made are attached
hereto and can also be seen at www.exiqon.com.


Additional information:
Lars Kongsbak, CEO, phone +45 45 66 08 88 (cell: +45 40 90 21 01)
Hans Henrik Chrois Christensen, CFO, phone +45 45 66 08 88 (cell: +45 40 90 21
31)

About Exiqon
Exiqon's products are based on the proprietary LNA? technology. This technology
offers unique advantages for detection of miRNA biomarkers for life science
researchers, drug developers and cancer treating physicians working towards
personalizing medicine. Exiqon operates in two business areas: Exiqon Life
Sciences has established a position for itself as one of the market's leading
providers of miRNA research products for miRNA analysis in cells. Our research
products are used by academia, biotech and pharmaceutical companies around the
world to make groundbreaking discoveries about the correlation between gene
activity and the development of cancer and other diseases. Exiqon Life Sciences
is also collaborating with pharmaceutical companies in their effort to develop
new medicines based on miRNA as biological markers (Exiqon Pharma Services).
Exiqon Diagnostics is developing a series of new molecular diagnostic products
based on miRNA. Exiqon's goal is to gain a market-leading position for
miRNA-based diagnostics. Exiqon is listed on the NASDAQ OMX in Copenhagen. For
more information about us, please visit www.exiqon.com.

Forward-looking statement:
Certain parts of this release contain forward-looking information with respect
to the plans, projections and future performance of the company, each of which
involves significant uncertainties. The company's actual results may differ
materially from the information set forth in these statements. This is an
English translation of the interim report prepared in Danish. In case of any
discrepancies between the Danish version and this English translation thereof,
the Danish version shall prevail.